Injectable cladribine suppresses the body's ability to make new blood cells (called [[Bone marrow suppression|Myelosuppression]]); data from HCL studies showed that about 70% of people taking the drug had [[Neutropenia|fewer white blood cells]] and about 30% developed infections and some of those progressed to [[septic shock]]; about 40% of people taking the drug had fewer [[red blood cells]] and became severely [[anemia|anemic]];  and about 10% of people had too few [[platelets]].<ref name=Label/>

 


 
At the dosage used to treat HCL in two clinical trials, 16% of people had rashes and 22% had nausea, the nausea generally did not lead to vomiting.<ref name=Label/>

 

